{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"methimazole-embryofetopathy","columns":[{"gene":"","key":"population-adb02ffa721534e5549b","label":"Methimazole embryofetopathy","mondoId":"MONDO:0016017","onsetQualifier":null,"originColumnKey":"MONDO:0016017/ORPHA:1923","originalViews":[{"key":"MONDO:0016017/ORPHA:1923","label":"Methimazole embryofetopathy","scopeLabel":"ORPHA:1923","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["0a473d4e9018cfed79881f801df382e52d5d64bf0df8aea48553de8ef8e4f6d0","14eb5ca1d4928edb8b7f5f3f8497fabbbbaa6a3cb2d5688e6d254ddecd679b48","1596aacdacda724410d7ca3cd2d0b66b795c7c8d38ef9620bd08f85cdfbcade3","22f1ea6be3398a78963fd540368668fb7ba6f4bc2498e71ab3b1a482e67ea514","29efa03b699098dd222edf5ad877fddbeff14cfbc30529bf6df4c7dcf4703430","62351ef5af04e0f60e8f8035de9df950f4157b70a73498cf132559da4125dfca","880543c3fe25542f3639ad0d2e9a7d0ab721095a4bdb7d8ae23aae546e0282b1","8bd3cfe53c24bb30e64629959fbeb1813b9ea090226a1e7087151b75e5cb047f","98b94a4e3785be2712f6e199f4aeea2079290ff122034de8676311f8bea12734","a3e0fc81332cd57365ca72085aad66f706fd644e31abccb9b5c832dda6fc6658","b56b69542a8ac533aa5d5cd6d66af0b4d6a8dc1e992847508bf90779b5f40cfd","f879d938ab82f539678576979b7df0722e5f360a3f0e9c153f5a97885e63c649","fd64868516af422a7529ed31d3b32f79695ca1016cb1619e539ade9ec9478380"],"recordQualifiers":{},"scopeLabel":"ORPHA:1923","sourceIds":["ORPHA:1923"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-adb02ffa721534e5549b"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001679","HP:0000820","HP:0001362","HP:0000453","HP:0001680","HP:0002032","HP:0000047"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":13,"sourceGroups":{"orphanet":13}},"features":[{"hpoId":"HP:0001679","label":"Abnormal aortic morphology","primary":true},{"hpoId":"HP:0000820","label":"Abnormality of the thyroid gland","primary":true},{"hpoId":"HP:0001362","label":"Calvarial skull defect","primary":true},{"hpoId":"HP:0000453","label":"Choanal atresia","primary":true},{"hpoId":"HP:0001680","label":"Coarctation of aorta","primary":true},{"hpoId":"HP:0002032","label":"Esophageal atresia","primary":true},{"hpoId":"HP:0000047","label":"Hypospadias","primary":true},{"hpoId":"HP:0000821","label":"Hypothyroidism","primary":false},{"hpoId":"HP:0001511","label":"Intrauterine growth retardation","primary":false},{"hpoId":"HP:0001561","label":"Polyhydramnios","primary":false},{"hpoId":"HP:0002575","label":"Tracheoesophageal fistula","primary":false},{"hpoId":"HP:0100589","label":"Urogenital fistula","primary":false},{"hpoId":"HP:0001629","label":"Ventricular septal defect","primary":false}],"ledeHtml":"Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves&#x27; disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.","mondoId":"MONDO:0016017","node":{"canonicalSlug":"methimazole-embryofetopathy","comparisons":[{"documentSha256":"2389389a45d013c51b3bcf4c3846c88a60d8a4f38625280ac08832a8d6aa0a60","key":"legacy-methimazole-embryofetopathy","kind":"legacy","label":"methimazole embryofetopathy","memberIds":["MONDO:0016017"],"mondoId":"MONDO:0016017","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/methimazole-embryofetopathy.2389389a45d013c51b3bcf4c3846c88a60d8a4f38625280ac08832a8d6aa0a60.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"methimazole embryofetopathy","paragraphs":["Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves' disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia."],"scope":"exact","source":"MONDO","upstream":"Orphanet:1923","url":"https://monarchinitiative.org/MONDO:0016017"},"ownColumnKeys":["population-adb02ffa721534e5549b"],"publication":"published","relationships":[{"kind":"parent","label":"syndromic disease","mondoId":"MONDO:0002254","slug":null},{"kind":"parent","label":"toxic or drug-related embryofetopathy","mondoId":"MONDO:0016677","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"0a473d4e9018cfed79881f801df382e52d5d64bf0df8aea48553de8ef8e4f6d0","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001680","is_excluded":false,"label":"Coarctation of aorta","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"14eb5ca1d4928edb8b7f5f3f8497fabbbbaa6a3cb2d5688e6d254ddecd679b48","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001362","is_excluded":false,"label":"Calvarial skull defect","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"1596aacdacda724410d7ca3cd2d0b66b795c7c8d38ef9620bd08f85cdfbcade3","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000821","is_excluded":false,"label":"Hypothyroidism","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"22f1ea6be3398a78963fd540368668fb7ba6f4bc2498e71ab3b1a482e67ea514","raw":{"aspect":"P","body_system":"growth","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001511","is_excluded":false,"label":"Intrauterine growth retardation","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"29efa03b699098dd222edf5ad877fddbeff14cfbc30529bf6df4c7dcf4703430","raw":{"aspect":"P","body_system":"respiratory","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002575","is_excluded":false,"label":"Tracheoesophageal fistula","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"62351ef5af04e0f60e8f8035de9df950f4157b70a73498cf132559da4125dfca","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000453","is_excluded":false,"label":"Choanal atresia","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"880543c3fe25542f3639ad0d2e9a7d0ab721095a4bdb7d8ae23aae546e0282b1","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001679","is_excluded":false,"label":"Abnormal aortic morphology","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8bd3cfe53c24bb30e64629959fbeb1813b9ea090226a1e7087151b75e5cb047f","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001629","is_excluded":false,"label":"Ventricular septal defect","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"98b94a4e3785be2712f6e199f4aeea2079290ff122034de8676311f8bea12734","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002032","is_excluded":false,"label":"Esophageal atresia","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"a3e0fc81332cd57365ca72085aad66f706fd644e31abccb9b5c832dda6fc6658","raw":{"aspect":"P","body_system":"prenatal","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001561","is_excluded":false,"label":"Polyhydramnios","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b56b69542a8ac533aa5d5cd6d66af0b4d6a8dc1e992847508bf90779b5f40cfd","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0100589","is_excluded":false,"label":"Urogenital fistula","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f879d938ab82f539678576979b7df0722e5f360a3f0e9c153f5a97885e63c649","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000820","is_excluded":false,"label":"Abnormality of the thyroid gland","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"fd64868516af422a7529ed31d3b32f79695ca1016cb1619e539ade9ec9478380","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1923","disease_name":"Methimazole embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000047","is_excluded":false,"label":"Hypospadias","onset_id":null,"reference":"ORPHA:1923","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0016017\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:1923</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Methimazole embryopathy is a teratogenic embryofetopathy that results from maternal exposition to methimazole (MMI; or the parent compound carbimazole) in the first trimester of pregnancy. MMI is an antithyroid thionamide drug used for the treatment of Graves&#x27; disease. In the infant, MMI may result in choanal atresia, esophageal atresia, omphalocele, omphalomesenteric duct anomalies, congenital heart disease (such as ventricular septal defect), renal system malformations and aplasia cutis. Additional features that may be observed include facial dysmorphism (short upslanting palpebral fissures, a broad nasal bridge with a small nose and a broad forehead) and athelia/hypothelia.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0016017\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"methimazole-embryofetopathy","sourceDocuments":[{"name":"MONDO: methimazole embryofetopathy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0016017"}],"sourceNote":"","synonyms":["fetal methimazole syndrome","foetal methimazole syndrome","Methimazole antenatal exposure","methimazole embryofetopathy","Methimazole/carbimazole embryofetopathy","Methimazole/carbimazole embryopathy","MMI/CMZ embryofetopathy","MMI/CMZ embryopathy"],"takeawayHtml":"","title":"methimazole embryofetopathy"},"schemaVersion":1}
